Jim Cramer Says He is a “Buyer of Novartis”

Core Insights - Novartis AG is recognized for its strong market position in branded pharmaceuticals, particularly in oncology, immunology, cardiovascular, renal, metabolic, and neurology sectors [1] - The company has undergone significant restructuring, including the recent spinoff of its Sandoz generics and biosimilars division, focusing solely on innovative medicines which now represent about 80% of revenue [1] - Novartis generates over 50% of its revenue from the Americas, approximately 30% from Europe, and nearly 20% from other regions [1] Financial Performance - Oncology accounts for 30% of Novartis' revenues, while immunology contributes almost 20%, and cardiovascular, renal, and metabolic areas also account for nearly 20% [1] - Mature branded products in non-core therapy areas contribute over 20% of the company's revenues [1] - Prior to the Sandoz spinoff, innovative medicines accounted for 85% of core operating income [1]